Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | GFPT1 | Q06210 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | HPGD | P15428 | 1/20 | 0.30 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18352646 | 0.95 | TSHR (0.38) | HCAR2KEAP1NFE2L2TSHRGAA | |
| SCHEMBL18355273 | 0.85 | HCAR2 (0.37) | HCAR2KEAP1NFE2L2TSHRGAA | |
| SCHEMBL18094733 | 0.83 | TSHR (0.56) | TSHRALOX15ALDH1A1HPGD | |
| SCHEMBL18355149 | 0.83 | HCAR2 (0.43) | HCAR2KEAP1NFE2L2TSHRGFPT1 | |
| SCHEMBL18418525 | 0.82 | HCAR2 (0.50) | HCAR2KEAP1NFE2L2TSHRGAA | |
| SCHEMBL18355350 | 0.81 | HCAR2 (0.42) | HCAR2KEAP1NFE2L2TSHRGAA | |
| SCHEMBL18355269 | 0.80 | SMN1; SMN2 (0.41) | HCAR2KEAP1NFE2L2TSHRGFPT1 | |
| SCHEMBL18352689 | 0.80 | TSHR (0.34) | HCAR2TSHRGAAALOX15TXNRD1 | |
| SCHEMBL28762368 | 0.79 | POLB (0.34) | GAAKDM4EALDH1A1HPGD | |
| SCHEMBL18352648 | 0.77 | TSHR (0.41) | HCAR2KEAP1NFE2L2TSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | Nguyen, Mark Quang (US) | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170001953-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | FH, FPGS, APC | HCAR2 290/4885KEAP1 468/4885NFE2L2 399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.